AFP与DNA倍体检测对原发性肝癌的预后价值  

The study of prognosis value of AFP and DNA ploidy detection in primary hepatic carcinoma

作　　者：李连欢 邓传娣[2] 

机构地区：[1]惠州市博罗县中医医院检验科,广东惠州516100 [2]中山大学附属肿瘤医院放疗科,广东广州510000

出　　处：《国际检验医学杂志》2015年第8期1115-1116,1119,共3页International Journal of Laboratory Medicine

摘　　要：目的研究惠州市博罗地区原发性肝癌(PHC)患者血清甲胎蛋白(AFP)水平和DNA倍体类型与PHC患者5年生存率及生存期的关系,评价其对PHC的预后价值。方法选取80例PHC患者纳入观察组,根据病理分级分为Ⅰ、Ⅱ、Ⅲ、Ⅳ级;另选取80例体检健康者纳入对照组。采集所有受试者的外周静脉血2mL,采用电化学发光免析法测定血清AFP水平,流式细胞术测定DNA倍体类型、DNA指数及S期细胞比率。结果不同病理分级PHC患者AFP水平均高于对照组,组间比较差异均有统计学意义(P<0.05),且随着PHC患者病理分级的增加而升高;患者血清AFP的升高、DNA倍体类型的不同和PHC的病理分级对患者的5年生存率和生存期都有很大的影响。结论惠州市博罗地区人群中,PHC患者血清AFP水平与DNA异倍体阳性率的检测对PHC的早期诊断和预后判断具有重要作用。Objective To investigate the relationship between the serum level of AFP ,types of DNA ploidy and 5 year survival rate ,survival time in patients with primary hepatic carcinoma （PHC） in Boluo area in Huizhou City ,and evaluate the prognosis val‐ue of these indexes in PHC .Methods 80 cases with PHC were enrolled in observation group and divided into grade I ,II ,III and IV according to pathological grading .Other 80 cases of healthy individuals ,conducted physical examination ,were enrolled in control group .Peripheral venous blood samples （2 mL） were collected from all subjects .The serum level of AFP and types of DNA ploidy were measured by electrochemiluminescence immunoassay （ECLIA） and flow cytometry ,respectively .Results The serum levels of AFP were significantly higher in patients in different pathological grade groups compared to that in the control group （P〈0 .05） .In addition ,accompany increase of pathological grade ,the levels of AFP in patients with PHC were increased .The increased level of AFP ,difference of DNA ploid types and pathological grade of PHC contributed great influences on the 5 year survival rate and survival time of patients .Conclusion The serum level of AFP and the DNA heteroploid rate may play important roles in the early diagnosis and assessing prognosis of patients with PHC in Boluo area in Huizhou City .

关 键 词：甲胎蛋白 DNA倍体 原发性肝癌 预后 

分 类 号：R735.7[医药卫生—肿瘤] R730.43[医药卫生—临床医学]